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Abstract
Background: Oxaliplatin is a platinum derivative, which is used in the treatment of colorectal
cancer. A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have
been reported. We present a case of hemolytic-uremic syndrome that developed during the 4th
cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.
Case presentation: A 52-year-old-male was administered chemotherapy with oxaliplatin, 5-
fluorouracil and leucovorin for a Duke's stage C colorectal carcinoma. Three cycles of
chemotherapy had been administered without complications when, at the beginning of the fourth
cycle, the patient developed clinical and laboratory abnormalities consistent with the development
of the hemolytic-uremic syndrome. Treatment was discontinued; the patient was managed with
monitored IV hydration and loop diuretics, high dose corticosteroids and fresh frozen plasma
infusions and recovered completely.
Conclusion: The hemolytic-uremic syndrome may be a rare complication of oxaliplatin-based
chemotherapy. Clinicians need to maintain a high index of suspicion to diagnose and treat this life-
threatening adverse event.
Background
Oxaliplatin (L-OHP) is a third generation platinum deriv-
ative with proven effectiveness in the treatment of color-
ectal cancer. Combined with 5-fluorouracil (5-FU) and
leucovorin as a 48 hour infusion every two weeks (FOL-
FOX regimen), L-OHP is drastic in the adjuvant, first and
second line setting [1]. Common adverse effects of this
regimen include reversible sensory neuropathy, myelo-
suppression and nausea [2]. Here, we describe a patient
who developed acute hemolysis and thrombocytopenia
after the 4th cycle of chemotherapy with FOLFOX.
Case presentation
A 52-year-old-male, with a prior history of non-insulin-
dependent diabetes mellitus, underwent sigmoidectomy
for a moderately differentiated adenocarcinoma of the sig-
moid colon. Pathologic staging revealed a Duke's stage C
tumor or C1 according to the Astler-Coller classification. A
decision was made to administer adjuvant chemotherapy
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using the FOLFOX-4 regimen (5-FU, 400 mg/m2 bolus
infusion on days 1, 2 followed by 5-FU, 600 mg/m2 as a
continuous infusion for 22 hours on days 1, 2, leucovorin
200 mg/m2 as a 2 hour infusion prior to 5-FU on days 1,
2 and L-OHP 85 mg/m2 on day 1, every 2 weeks). He was
programmed to receive a total of 6 monthly cycles. Treat-
ment was well tolerated until the 4th cycle, at the begin-
ning of which the patient's hematologic profile and renal
function were normal (Hb: 13,8 g/dl, HCT: 43%, WBC:
4,9 × 109cells/L, platelets: 162 × 103 cells/μg, creatinine:
1,1 mg/dl, BUN: 35 mg/dl).
On the first day of therapy, and after L-OHP infusion was
completed, the patient noticed urine discoloration and
immediate urine analysis demonstrated hematuria with
hemoglobinuria. During the next day, the patient's com-
plete blood count exhibited findings consistent with acute
hemolysis and thrombocytopenia (Hb: 12 g/dl, Hct: 36%,
WBC: 4,78 × 109 cells/L and platelets: 50 × 103 cells/μl). A
hemolytic reaction was indicated by elevated LDH and
indirect bilirubin indices (1383 U/l and 3,34 mg%,
respectively). The patient also exhibited signs of acute
anuric renal failure (urea: 77 mg%, serum creatinine: 3,1
mg% and uric acid: 9,5 mg%). Peripheral smear analysis
demonstrated fragmented RBCs.
Chemotherapy was immediately discontinued and the
patient was managed conservatively with monitored IV
hydration and loop diuretics, high dose corticosteroids
and fresh frozen plasma (FFP) infusions on a daily basis.
The development of hemolysis was further substantiated
with next day's laboratory results. LDH remained elevated
at 819 U/l. Coagulation parameters were normal, partial
thromboplastin time, fibrinogen and INR were 31,1 sec,
412 mg/dl and 1.05, respectively. D-dimmers were 9,1 μg/
ml. The patient was not G6-PD deficient (G6-PD: 11.0 U/
g Hb). Direct and indirect agglutination reactions
remained negative providing no indication of immune
mediated hemolysis. Hemoglobin and hematocrit values
reached a minimum of 11.8 g/dl and 34.8% respectively,
four days after the infusion of L-OHP. At that point, LDH
was 499 U/l and BUN and creatinine were 149 mg/dl and
5,6 mg/dl, respectively.
The patient gradually recovered and the results of succes-
sive hematological and biochemical tests confirmed the
improvement of his condition. Fifteen days after the onset
of hemolysis and thrombocytopenia laboratory values
were returning to normal: Hb: 12,1 g/dl, Hct: 38,2%,
platelets: 151 × 103 cells/μl, LDH: 255 U/l, creatinine: 1,5
mg/dl, BUN: 78 mg/dl. A month later, all hematologic
values and the urine analysis had returned to normal. The
patient refused the continuation of chemotherapy. On
follow-up, one year after the hemolytic episode, the
patient remained disease free and asymptomatic, with no
evidence of recurrence of hemolysis or thrombocytope-
nia. BUN and creatinine were 42 mg/dl and 1,2 mg/dl,
respectively, indicating the absence of chronic renal
sequelae.
Discussion
The combination of L-OHP with 5-fluorouracil/leucov-
orin (FOLFOX) has proven efficacy in the treatment of
advanced colorectal cancer [1]. Common adverse effects
of this drug combination are neutropenia, diarrhea, and
most importantly, reversible sensory neuropathy [2]. Lit-
erature reports of L-OHP-related acute hemolysis and/or
thrombocytopenia are scarce [3-11]. The pathogenetic
mechanisms underlying this condition are controversial.
The present case clearly demonstrated signs of acute intra-
vascular hemolysis associated with thrombocytopenia
and renal impairment.
Three mechanisms have been considered for the patho-
genesis of hemolysis with thrombocytopenia associated
with L-OHP-based chemotherapy: (a) antibody mediated
destruction of platelets and erythrocytes (b) microangio-
pathic hemolytic anemia due to drug-induced thrombotic
thrombocytopenic purpura (TTP), and (c) microangio-
pathic hemolytic anemia due to disseminated intravascu-
lar coagulation (DIC) [9,10]. In the present case, DIC was
readily excluded, since D-dimmers were only slightly ele-
vated and aPPT and INR values were normal. Review of
the literature on all reported cases of hemolysis and/or
thrombocytopenia related to L-OHP, was negative for the
presence of DIC.
Antibody mediated hemolysis and/or thrombocytopenia
is considered the most common etiology for a clinical
presentation similar to that exhibited by our patient. An
immune-complex type hemolytic anemia has been postu-
lated as a possible pathogenetic mechanism [5]. Hemoly-
sis provoked by the adsorption of L-OHP on the surface of
red blood cells (RBCs) has also been considered a proba-
ble cause or contributing factor [3,8]. Such a phenome-
non is invariably associated with a positive direct
agglutination test (direct Coomb's reaction), which was
not present in our case. Moreover, the presence of anti-
bodies against both the RBCs and the platelets (com-
monly termed the "Evans' syndrome") is a rare cause of
drug induced hemolysis and thrombocytopenia, and
there have been few reports of L-OHP induced Evan's syn-
drome in the literature [6,9].
The hemolytic uremic syndrome (HUS) and TTP are the
most common manifestations of a group of disease states
termed "thrombotic microangiopathies". The distinction
between these two conditions is difficult on clinical
grounds [12]. A classic pentad of signs has been associatedBMC Clinical Pharmacology 2006, 6:5 http://www.biomedcentral.com/1472-6904/6/5
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with TTP: microangiopathic hemolytic anemia, thrombo-
cytopenia, neurological abnormalities, renal failure and
fever. In practice, the combination of thrombocytopenia
and hemolytic anemia, in the absence of any apparent
alternative cause is enough to suggest the presence of TTP
or HUS. If renal failure dominates the clinical picture,
then the disorder is considered the HUS [13-15].
Our patient exhibited laboratory values consistent with
the HUS (hemolytic anemia, elevated LDH, normal coag-
ulation parameters, negative findings on the DAT, and
acute renal failure). A number of drugs have been impli-
cated as causal agents of thrombotic microangiopathy,
either as an acute, immune-mediated toxicity (quinine,
ticlodipine, clopidogrel) or as a cumulative, dose-depend-
ent toxicity (mitomycin-C, gemcitabine) [12-18]. The
sudden onset of hemolysis and thrombocytopenia in our
patient seems to favor an immune-mediated reaction. Any
of the administered drugs could have been responsible for
this reaction. Development of the HUS has been reported
as a severe toxicity of 5-FU/leucovorin chemotherapy,
almost always in combination with mitomycin-C or other
agents known to cause HUS/TTP [18-21]. It has been sug-
gested that 5-FU/leucovorin may increase the incidence of
mitomycin-C induced HUS. We cannot exclude the occur-
rence of such a synergistic effect in our patient. Since no
further 5-FU-based chemotherapy was administered, any
potential role of 5-FU/leucovorin in the development of
HUS cannot be definitively ruled out. To our knowledge,
this is the first case of L-OHP-related HUS reported in the
literature.
The treatment of drug related HUS remains controversial
[15,16,18]. Mainstays of treatment include the discontin-
uation of the offending agent, supportive care and FFP
infusion [13-16]. Some investigators favor plasma
exchange to FFP infusions, although the superiority of
either method in the management of this patient popula-
tion has not been proven [15]. In the present case,
response was favorable to conservative management.
Conclusion
Acute hemolysis, with or without thrombocytopenia, is a
rare but potentially life-threatening complication of L-
OHP-based chemotherapy. We described the case of a
patient who developed the HUS after the 4th cycle of FOL-
FOX chemotherapy and was successfully managed. In
view of the relatively recent approval of L-OHP from the
FDA (August, 2002), and the expected broad application
of this agent in a variety of solid tumors [22], the inci-
dence of acute hematological events related to its use will
likely increase. Thus, increased vigilance on behalf of the
oncologic community is required.
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